Aranesp® (darbepoetin alfa) administered once every 2 weeks (Q2W) maintains recommended haemoglobin (hb) in chronic kidney disease (ckd) patients on haemodialysis switched from weekly (QW) dosing

被引：0

作者：

Carrera, Fernando ^{[1
]}

Oliveira, Lino ^{[1
]}

Maia, Pedro ^{[1
]}

Mendes, Teresa ^{[1
]}

Ferreira, Candido ^{[1
]}

机构：

[1] Eurodial, Dialysis Unit, Leiria, Portugal

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

引用

页码：148 / 149

页数：2

共 50 条

[21] Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: Results from Simplify the Treatment of Anemia with Aranesp (STAAR)
Hertel, J
Locay, H
Scarlata, D
Jackson, L
Prathikanti, R
Audhya, P
AMERICAN JOURNAL OF NEPHROLOGY, 2006, 26 (02) : 149 - 156
[22] Early results of a head-to-head comparison of darbepoetin alfa 200 mcg given every 2 weeks (Q2W) and epoetin alfa 40,000 U given weekly (QW)
Schwartzberg, LS
Yee, LK
Senecal, FM
Charu, V
Yao, B
Mendes, E
Rossi, G
BLOOD, 2003, 102 (11) : 515A - 515A
[23] Comparable efficacy and safety of darbepoetin alfa 200 mcg every 2 weeks (Q2W) and epoetin alfa 40,000 U weekly (QW) in patients (pts) with breast cancer: results of a randomized comparison
Schwartzberg, LS
Lee, LK
Charu, V
Tomita, D
Rossi, G
Senecal, FM
BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S230 - S230
[24] CERA ONCE EVERY 4 WEEKS (Q4W) CORRECTS ANAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) NOT ON DIALYSIS AND DEMONSTRATES COMPARABLE SAFETY TO DARBEPOETIN ALFA
Roger, S.
NEPHROLOGY, 2010, 15 : 79 - 80
[25] Intravenous (iv) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (HB) levels in patients with chronic kidney disease (CKD) on dialysis
Canaud, Bernard
Braun, Johann
Locatelli, Francesco
Villa, Giuseppe
Van Vlem, Bruno
Guajardo, Damaso Sanz
Dougherty, Frank C.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 157 - 157
[26] An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study
Galle, Jan-Christoph
Claes, Kathleen
Kiss, Istvan
Winearls, Christopher G.
Herlitz, Hans
Guerin, Alain
Di Giulio, Salvatore
Suranyi, Michael G.
Bridges, Ian
Addison, Janet
Farouk, Mourad
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (06) : 2303 - 2311
[27] Once-weekly (QW) darbepoetin alfa administration in erythropoiesis-stimulating protein (ESP)-naive patients with chronic kidney disease (CKD): Hemoglobin (HB) levels within the first 8 weeks of therapy
Kewalramani, Reshma
Chen, Chao-Yin
Klassen, Preston
AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (04) : A53 - A53
[28] Preliminary efficacy findings from the alternate study:: A long-term non-interventional trial to evaluate the effectiveness of aranesp® (darbepoetin alfa; DA) in dialysis patients (pts) when administered once every two weeks (Q2W)
Pronai, W.
DeMeester, J.
McMahon, L.
Rottembourg, J.
Simon, P.
Merrell, E.
Walsh, C.
Molemans, B.
Feriani, M.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 351 - 352
[29] Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis-stimulating agents
Silver, M. R.
Geronemus, R.
Krause, M.
Chen, C. Y.
Kewalramani, R.
Stehman-Breen, C.
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 123 - 131
[30] Darbepoetin alfa 200 mcg every 2 weeks (Q2W) and epoetin alfa 40,000 units every week (QW) in chemotherapy-induced anemia patients result in similar initial hemoglobin outcomes
Patton, J
Wallace, JF
VALUE IN HEALTH, 2003, 6 (03) : 228 - 228

← 1 2 3 4 5 →